These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6542793)

  • 1. [Plasma levels of fosfestrol and its monophosphate, of diethylstilbestrol and its monoglucuronide following intravenous administration in patients with metastatic prostatic carcinoma].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1984; 34(10):1333-6. PubMed ID: 6542793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Plasma concentrations of fosfestrol as well as diethylstilbestrol on their conjugates following intravenous administration on prostatic carcinoma patients].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1986 Aug; 36(8):1284-9. PubMed ID: 3778569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1988 Oct; 38(10):1502-12. PubMed ID: 3058134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Direct determination of diethylstilbestrol and its monoconjugates in plasma].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1986 Apr; 36(4):759-63. PubMed ID: 3718601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Direct approximation of plasma concentration time curves of 3-diethylstilbestrol monoglucuronide following oral and intravenous administration of fosfestrol].
    Rothley D; Oelschläger H
    Pharmazie; 1986 Dec; 41(12):862-4. PubMed ID: 3575391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Honvan-high-dose therapy of prostatic carcinoma with metastases: early complications and value of prophylaxis against thrombosis].
    Heinz A; Meyer WW; Hallwachs O
    Urologe A; 1982 Jul; 21(4):232-4. PubMed ID: 6890263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability, distribution and pharmacokinetics of diethylstilbestrol converted from diethylstilbestrol diphosphate in patients with prostatic cancer.
    Nakamura K
    Hiroshima J Med Sci; 1986 Dec; 35(4):325-38. PubMed ID: 3570844
    [No Abstract]   [Full Text] [Related]  

  • 8. The pharmacokinetics of fosfestrol and diethylstilbestrol in chronic hemodialysis patients with prostate cancer.
    Hatori M; Totuka Y; Yamanaka H
    Int J Urol; 2001 Dec; 8(12):681-5. PubMed ID: 11851768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunoassay of diethylstilbestrol in plasma of patients with prostatic carcinoma.
    Usui T; Nakamura K; Osumi T; Ishibe T; Kitano T; Kambegawa A; Miyachi Y
    Arch Androl; 1984; 12(2-3):243-9. PubMed ID: 6508431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate.
    Ahmed M; Choksy S; Chilton CP; Munson KW; Williams JH
    Int Urol Nephrol; 1998; 30(2):159-64. PubMed ID: 9607886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenocortical insufficiency associated with long-term high-dose fosfestrol therapy for prostatic carcinoma.
    Iida H; Miyamoto I; Noda Y; Sawaki M; Nagai Y
    Intern Med; 1999 Oct; 38(10):804-7. PubMed ID: 10526944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay of the synthetic estrogen fosfestrol in pharmaceutical formulations using capillary electrophoresis.
    G Themelis D; Trellopoulos AV; Tzanavaras PD; Karlberg B
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):559-63. PubMed ID: 15953702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 125I-radioimmunoassay for diethylstilbestrol in serum of patients with prostatic cancer treated with stilphostrol.
    Economou EV; Livaniou E; Evangelatos GP; Ithakissios DS
    Clin Chim Acta; 1993 Jul; 216(1-2):81-90. PubMed ID: 8222276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate.
    Droz JP; De Smedt E; Kattan J; Keuppens F; Khoury S; Mahler C; Denis L
    Prostate; 1994; 24(2):62-6. PubMed ID: 7508621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.
    Sotaniemi EA; Kontturi M; Larmi TK
    Invest Urol; 1973 May; 10(6):438-41. PubMed ID: 4704169
    [No Abstract]   [Full Text] [Related]  

  • 16. [High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma].
    Kattan J; Droz JP; Culine S
    Bull Cancer; 1993 Mar; 80(3):248-54. PubMed ID: 8173177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experiences with Honvan therapy in carcinoma of the prostate].
    Joó GD
    Med Welt; 1966 Jan; 1():61-4. PubMed ID: 5942368
    [No Abstract]   [Full Text] [Related]  

  • 18. Measurement of diethylstilbestrol in plasma from patients with cancer of the prostate.
    Kemp HA; Read GF; Riad-Fahmy D; Pike AW; Gaskell SJ; Queen K; Harper ME; Griffiths K
    Cancer Res; 1981 Nov; 41(11 Pt 1):4693-7. PubMed ID: 7306985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of prostatic cancer metastasis by high doses of diethylstilbestrol diphosphate.
    Susan LP; Roth RB; Adkins WC
    Urology; 1976 Jun; 7(6):598-601. PubMed ID: 936380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.